Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)

Next Previous
X
Search
Trial Profile

Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 02 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Brain metastases; Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms CHECKMATE 920
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 25 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 16 Nov 2021 Results assessing safety and efficacy of NIVO + IPI in a cohort that included patients with aRCC and brain metastases published in the Cancer
    • 08 Jun 2021 Updated Results (n=28) evalauting safety and efficacy results for the cohort of patients with aRCC of any histology and brain metastases, presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top